Cel-Sci Corporation (CVM)
CVM trades on NYSE in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CVM on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 1997 |
| SEC CIK | 0000725363 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | CO |
Financials
No annual revenue filed since the period ending 2014-09-30.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-08-14 |
| Cash and burn | $6.5M cash; operating cash flow -$4.2M a quarter. | Report 2026-06-30 |
| Shares outstanding | 17,588,987 (2026-08-10); 6,882,156 a year earlier; 47,260,097 three years earlier. 3y figure adjusted for splits (1-for-30 overall). | Cover page 2026-08-10 |
| Reverse splits, 3 years | 1; latest 1-for-30 on 2025-05-20 | Source 2025-05-20 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-15 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., Potomac, Maryland, United States | PCAOB Form AP 2025-12-29 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $867K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-06-30 | Not filed | -$5.7M | -$4.0M | $6.5M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q2 2026 2026-03-31 | Not filed | -$5.5M | -$4.0M | $1.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2026 2025-12-31 | Not filed | -$5.5M | -$4.0M | $6.3M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2025 2025-09-30 | Not filed | -$6.1M | -$4.7M | $11.0M | $8.0M | Needs four quarters | 10-K 2025-12-29 |
| Q3 2025 2025-06-30 | Not filed | -$5.7M | -$3.9M | $1.8M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q2 2025 2025-03-31 | Not filed | -$6.6M | -$4.4M | $1.9M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q1 2025 2024-12-31 | Not filed | -$7.1M | -$4.1M | $4.6M | No debt tags | Needs four quarters | 10-Q 2026-08-14 |
| Q4 2024 2024-09-30 | Not filed | -$6.1M | -$4.8M | $4.7M | No debt tags | Needs four quarters | 10-K 2025-12-29 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-06-15 |
| Latest annual report FORM 10-K | 10-K | 2025-12-29 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-08-14 |
| Latest current report FORM 8-K | 8-K | 2026-08-17 |
| Latest proxy | DEF 14A | 2026-07-02 |
Source: SEC EDGAR submissions feed, 1,007 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.7% |
| 1 month | -26.9% |
| 3 months | -14.1% |
| Year to date | -75.7% |
| 1 year | -80.7% |
| From 52-week high | -83.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INMB | INmune Bio Inc. | $0.9464 | -9.87% | $29.3M |
| SAEN | Genenta Science S.p.A. | $0.6000 | -7.66% | $28.9M |
| PTHS | Pelthos Therapeutics Inc. | $7.15 | -3.90% | $28.1M |
| LONA | LeonaBio Inc. | $3.23 | -6.92% | $30.4M |
| MGX | Metagenomi Therapeutics Inc. | $0.6800 | -1.69% | $25.7M |
| EVAX | Evaxion A/S American Depositary Share | $2.77 | +0.54% | $25.5M |
| KLRS | Kalaris Therapeutics Inc. | $1.46 | -7.30% | $34.8M |
| ELUT | Elutia Inc. | $0.8229 | +0.35% | $36.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier